tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
BIIB is currently covered by 28 analysts with an average price target of $198.26. This is a potential upside of $52.03 (35.58%) from yesterday's end of day stock price of $146.23.
Biogen's activity chart (see below) currently has 880 price targets and 732 ratings on display. The stock rating distribution of BIIB is 80.39% BUY and 19.61% HOLD.
Analysts average stock forecasts to be materialized ratio is 64.42% with an average time for these price targets to be met of 236.72 days.
Highest price target for BIIB is $340, Lowest price target is $138, average price target is $198.26.
Most recent stock forecast was given by MOHIT BANSAL from WELLS FARGO on 10-Jan-2025. First documented stock forecast 09-Sep-2010.
BiogenĀ is focused on the discovery, development, manufacturing innovative therapies for the treatment of neurological and neurodegenerative diseases.
Biogen offers a diverse portfolio of therapies targeting various neurological conditions.
For multiple sclerosis (MS), the company provides products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which aim to manage and alleviate the symptoms of this chronic autoimmune disease.
Biogen’s SPINRAZA is a groundbreaking therapy for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that affects muscle movement. The company’s innovative treatment, ADUHELM, addresses Alzheimer’s disease, a progressive neurodegenerative disorder characterized by cognitive decline.
In addition to MS, SMA, and Alzheimer’s disease, Biogen’s product lineup encompasses various therapeutic areas. The company offers FUMADERM to treat plaque psoriasis, a chronic skin condition. BENEPALI, IMRALDI, and FLIXABI are biosimilars developed by Biogen, referencing well-established therapies for conditions like rheumatoid arthritis and certain types of cancer.
Furthermore, Biogen delivers therapies like RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab to address a range of disorders, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and other immunological and neurovascular conditions.
Biogen’s headquarters are located in Cambridge, Massachusetts, since it was founded in 1978.
Currently out of the existing stock ratings of BIIB, 123 are a BUY (80.39%), 30 are a HOLD (19.61%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$165
$18.8 (12.86%)
$225
20 days ago
(10-Jan-2025)
9/16 (56.25%)
$16.98 (11.47%)
225
Buy
$138
$-8.2 (-5.61%)
$313
28 days ago
(02-Jan-2025)
32/46 (69.57%)
$-15.62 (-10.17%)
418
Buy
$164
$17.8 (12.18%)
$230
1 months 10 days ago
(20-Dec-2024)
18/25 (72%)
$16.61 (11.27%)
215
Buy
$175
$28.8 (19.70%)
$287
1 months 14 days ago
(16-Dec-2024)
15/25 (60%)
$23.59 (15.58%)
215
Hold
$178
$31.8 (21.75%)
$190
1 months 20 days ago
(10-Dec-2024)
12/20 (60%)
$22.15 (14.21%)
180
What is BIIB (Biogen) average time for price targets to be met?
Which analyst has the current highest performing score on BIIB (Biogen) with a proven track record?
Which analyst has the most public recommendations on BIIB (Biogen)?
Which analyst is the currently most bullish on BIIB (Biogen)?
Which analyst is the currently most reserved on BIIB (Biogen)?
